Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin Bolus vs Continuous Drip in Refractory Septic Shock
NCT00793559Phase 2
Key facts
- Status
- Unknown
- Start
- Nov 2008
- Primary completion
- Jul 2009
- Countries
- 1
- Sponsor
- Shamir Medical Center
- Modality
- Peptides, Small Molecules
- Drugs
- terlipressin
- Conditions
- septic shock
01
Overview
Phase 2, randomised, open-label trial of terlipressin in septic shock (2 arms), sponsored by Shamir Medical Center. Primary endpoints: Cardiac Index at 6 months, Systemic Vascular Resistance at 6 months and 4 more. Status: unknown.
02
Design
2 arms- Study design
- RandomizedOpen-label
Terlipressin Bolus
1 mg terlipressin bolus + SOC (Noradrenaline)
Terlipressin Drip
1 mg terlipressin continuous drip (6h) + SOC (Noradrenaline)
03
Who it enrols
Septic shock patients receiving > 0.5 mcg/kg noradrenaline. Excludes allergy to terlipressin, CHF, IHD, pregnancy.
04
Endpoints
Primary
Cardiac Index
Systemic Vascular Resistance
Heart Rate
Blood Pressure
Noradrenalin administration
Beyond the preview
Go deeper on NCT00793559.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00793559.